White Paper
Expediting innovative drugs' market access in China
Mar 17, 2021
Download

China's reform on drug review and approval policy has made remarkable achievements in the past few years. However, patients in China are still facing challenges brought by the inaccessibility of innovative drugs. Through research on innovative drugs approved by regulatory bodies such as the FDA, EMA, PMDA and NMPA between January 2009 to June 2019, we found that innovative drugs, inaccessible in China, can effectively reduce patients' disease burden. Therefore, the timely introduction of innovative drugs into the Chinese market is of great importance to provide more treatment options and meet the medical needs of patients.

This article was produced as part of the IQVIA APAC Insight magazine, to read the full publication please click here 

Contact Us